Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 3, 2016, Pages

  Sepúlveda, Maria ^a   Armangué, Thaís ^a   Sola Valls, Nuria ^a   Arrambide, Georgina ^b   Meca Lallana, José E ^c   Oreja Guevara, Celia ^d   Mendibe, Mar ^e   De Arcaya, Amaya Alvarez ^f   Aladro, Yolanda ^g   Casanova, Bonaventura ^h   Olascoaga, Javier ⁱ   Jiménez Huete, Adolfo ^j   Fernández Fournier, Mireya ^k   Ramió Torrentà, Lluis ^l   Cobo Calvo, Alvaro ^m   Viñals, Montserrat ⁿ   De Andrés, Clara ^o   Meca Lallana, Virginia ^p   Cervelló, Angeles ^q   Calles, Carmen ^r   Rubio, Manuel Barón ^s   Ramo Tello, Cristina ^t   Caminero, Ana ^u   Munteis, Elvira ^v   Antigüedad, Alfredo R ^w   Blanco, Yolanda ^a   Villoslada, Pablo ^a   Montalban, Xavier ^b   Graus, Francesc ^a   Saiz, Albert ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j HOSPITAL RUBER INTERNACIONAL   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ UNIVERSITY OF CÓRDOBA   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^p HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^q HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^r HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^s HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^t HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^u HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^v HOSPITAL DEL MAR   (Spain)

^w HOSPITAL DE BASURTO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELITIS; MYELOOPTIC NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROLOGY; SEX DIFFERENCE;

EID: 85011863406     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000225     Document Type: Article

References (17)

1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66: 1485-1489.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
3. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-179.
4. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
5. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135: 1834-1849.
6. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.
7. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibodypositive NMO spectrum disorders. Neurology 2014;82: 474-481.
8. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-283.
9. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015;21:866-874.
10. Barkhof F, Filippi M, Miller D, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120: 2059-2069.
11. Höftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. PLoS One 2013;8:e79083.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
13. Nagaihi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011;82:1360-1364.
14. Jiao Y, Fryer JP, Lennon VA, et al. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol 2014;71: 48-54.
15. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin- 4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-2200.
16. Cobo-Calvo A, Sepúlveda M, Bernard-Valnet R, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler 2016;22:312-319.
17. Di Pauli F, Höftberger R, Reindl M, et al. Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm 2015;2:e175.